Elanco’s ZORBIUM Buprenorphine Transdermal Solution Gains U.S. Approval
Elanco's ZORBIUM™ (Buprenorphine Transdermal Solution) – the First Long-Acting Transdermal Buprenorphine for Cats - Gains U.S. Approval
FDA issues approval for new, prescription medication to control
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
Before 10 am on Friday, 110 companies set new 52-week lows.
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
The Daily Biotech Pulse: NRx’s Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours.
Elanco Animal Health Q3 Adj. EPS $0.19 Beats $0.16 Estimate, Sales $1.13B Beat $1.08B Estimate
Elanco Animal Health (NYSE:ELAN) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.16 by 18.75 percent. This is a 46.15 percent increase over earnings of $0.13 per share from
Earnings Scheduled For November 5, 2021
Companies Reporting Before The Bell
• Brookfield Renewable (NYSE:BEPC) is projected to report earnings for its third quarter.
Earnings Preview For Elanco Animal Health
Elanco Animal Health (NYSE:ELAN) is set to give its latest quarterly earnings report on Friday, 2021-11-05. Here's what investors need to know before the announcement.
Analysts estimate that Elanco Animal Health will likely report an Earnings Per Share (EPS) of $0.16